Bristol-Myers Squibb Company Ce
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELG-RI research report →
Price Chart
About the company
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
- CEO
- Christopher S. Boerner
- IPO
- 2019
- Employees
- 34,100
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on CELG-RI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $203.76M
- P/E
- 0.00
- Fwd P/E
- 0.01
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
- Gross Margin
- 96.16%
- Op Margin
- 33.97%
- Net Margin
- 26.48%
- ROE
- 61.86%
- ROIC
- 13.62%
Latest fiscal year · YoY change
- Revenue
- $15.28B+17.5%
- Gross Profit
- $14.69B+17.2%
- Op Income
- $5.19B
- Net Income
- $4.05B+37.6%
- EPS
- $5.51+46.2%
- OCF Growth
- -1.4%
- FCF Growth
- -2.5%
- 52W High
- $0.10
- 52W Low
- $0.09
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- -0.52
- RSI (14)
- 48
- Avg Volume
- 27.40K
No earnings-call transcripts are available for CELG-RI yet.
- Free Float
- 99.7%
- Shares Outstanding
- 2.04B
- Float Shares
- 2.04B
of shares held by institutions
17 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Watts Gwilliam & Co., LLC | 20.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 20, 19 | VESSEY RUPERT | other | 24,209 |
| Nov 20, 19 | VESSEY RUPERT | other | 13,906 |
| Nov 20, 19 | VESSEY RUPERT | other | 8,634 |
| Nov 20, 19 | VESSEY RUPERT | sell | 18,257 |
| Nov 20, 19 | VESSEY RUPERT | sell | 18,257 |
| Nov 20, 19 | VESSEY RUPERT | sell | 613 |
| Nov 20, 19 | VESSEY RUPERT | sell | 26,308 |
| Nov 20, 19 | VESSEY RUPERT | sell | 3,125 |
| Nov 20, 19 | VESSEY RUPERT | sell | 12,906 |
| Nov 20, 19 | VESSEY RUPERT | sell | 11,384 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CELG-RI coverage
Recent articles, reports, and earnings notes.
No research on CELG-RI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELG-RI report →